KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

W Robert Lee, James J Dignam, Mahul B Amin, Deborah W Bruner, Daniel Low, Gregory P Swanson, Amit B Shah, David D'Souza, Jeff M Michalski, Ian S Dayes, Samantha A Seaward, William A Hall, Paul L Nguyen, Thomas M Pisansky, Sergio L Faria, Yuhchyau Chen, Joseph P Rodgers, Howard M Sandler

J Clin Oncol 42(20) 2377-2381

PMID38759121
PMCIDPMC11377096
DOI10.1200/JCO.23.02445
发表日期2024-05-17
入排依据:The study is an eligible Phase III randomized trial with a time-to-event endpoint, but the intervention is radiotherapy alone, not a drug-containing intervention. It does not meet the inclusion criterion for a drug-containing intervention.
摘要

摘要

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.NRG Oncology RTOG 0415 is a randomized phase III noninferiority (NI) clinical trial comparing conventional fractionation (73.8 Gy in 41 fractions) radiotherapy (C-RT) with hypofractionation (H-RT; 70 Gy in 28) in patients with low-risk prostate cancer. The study included 1,092 protocol-eligible patients initially reported in 2016 with a median follow-up of 5.8 years. Updated results with median follow-up of 12.8 years are now presented. The estimated 12-year disease-free survival (DFS) is 56.1% (95% CI, 51.5 to 60.5) for C-RT and 61.8% (95% CI, 57.2 to 66.0) for H-RT. The DFS hazard ratio (H-RT/C-RT) is 0.85 (95% CI, 0.71 to 1.03), confirming NI (P < .001). Twelve-year cumulative incidence of biochemical failure (BF) was 17.0% (95% CI, 13.8 to 20.5) for C-RT and 9.9% (95% CI, 7.5 to 12.6) for H-RT. The HR (H-RT/C-RT) comparing biochemical recurrence between the two arms was 0.55 (95% CI, 0.39 to 0.78). Late grade ≥3 GI adverse event (AE) incidence is 3.2% (C-RT) versus 4.4% (H-RT), with relative risk (RR) for H-RT versus C-RT 1.39 (95% CI, 0.75 to 2.55). Late grade ≥3 genitourinary (GU) AE incidence is 3.4% (C-RT) versus 4.2% (H-RT), RR 1.26 (95% CI, 0.69 to 2.30). Long-term DFS is noninferior with H-RT compared with C-RT. BF is less with H-RT. No significant differences in late grade ≥3 GI/GU AEs were observed between assignments (ClinicalTrials.gov identifier: NCT00331773).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。